Physician profile
Julia Moses
NPI 1982368320
$2,529.17
in general payments reported to CMS, 2019-2025
18 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $271 · 2023: $464 · 2024: $586 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,125 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.10 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.83 | 2022-2025 | |
| Qol Medical, LLC | $346.81 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $259.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $118.67 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $118.02 | 2022-2023 | Dupixent |
| Janssen Biotech, INC. | $114.94 | 2022-2025 | Tremfya, Stelara |
| Astrazeneca Pharmaceuticals LP | $100.52 | 2023 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.22 | 2021-2023 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $84.32 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $80.23 | 2021-2025 | Eohilia |
| Ardelyx, INC. | $77.07 | 2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $51.17 | 2024 | Givlaari |
| Janssen Scientific Affairs, LLC | $50.01 | 2024 | Tremfya |
| Amarin Pharma, INC. | $44.02 | 2021-2022 | |
| Lilly USA, LLC | $41.13 | 2021-2023 | Mounjaro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $19.19 | 2025 | Zenpep |
| Gilead Sciences, INC. | $16.32 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.